Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© Springer International Publishing Switzerland 2016. The use of drugs that inhibit bone resorption (“antiresorptives”) continues to dominate the therapy of bone diseases, many of which are characterized by enhanced bone destruction. These disorders include not just osteoporosis but also Paget’s disease of bone, myeloma, and bone metastases secondary to breast, prostate, and other cancers, as well as many less common acquired or inherited diseases such as osteogenesis imperfecta. For osteoporosis, treatments have historically included hormones, such as estrogens as well as calcitonins. Several SERMs (selective estrogen receptor modulators) have been developed, among which raloxifene and bazedoxifene are quite widely used. Currently, the mainstay of treatment worldwide is still with bisphosphonates, which have been used clinically for more than 40 years and can reduce fracture occurrence at vertebral and non-vertebral sites, including hips. The most recently introduced new drug is the anti-RANK-ligand antibody, denosumab, which is also effective against these fractures. Several cathepsin K inhibitors have also been studied, but, among these, only odanacatib is close to being likely to be registered for clinical use. The pharmacological basis for the action of each of these drug classes is different, but reasonably well understood, and needs to be considered when determining the optimal ways they can be used in clinical practice.

Original publication

DOI

10.1007/978-3-319-23639-1_2

Type

Chapter

Book title

The Duration and Safety of Osteoporosis Treatment: Anabolic and Antiresorptive Therapy

Publication Date

01/01/2015

Pages

17 - 36